We are analyzing https://link.springer.com/article/10.1186/s12967-017-1378-2.

Title:
Gamma-delta (γδ) T cells: friend or foe in cancer development? | Journal of Translational Medicine
Description:
Background γδ T cells are a distinct subgroup of T cells containing T cell receptors (TCRs) γ and TCR δ chains with diverse structural and functional heterogeneity. As a bridge between the innate and adaptive immune systems, γδ T cells participate in various immune responses during cancer progression. Because of their direct/indirect antitumor cytotoxicity and strong cytokine production ability, the use of γδ T cells in cancer immunotherapy has received a lot of attention over the past decade. Main text Despite the promising potential of γδ T cells, the efficacy of γδ T cell immunotherapy is limited, with an average response ratio of only 21%. In addition, research over the past 2 years has shown that γδ T cells could also promote cancer progression by inhibiting antitumor responses, and enhancing cancer angiogenesis. As a result, γδ T cells have a dual effect and can therefore be considered as being both “friends” and “foes” of cancer. In order to solve the sub-optimal efficiency problem of γδ T cell immunotherapy, we review recent observations regarding the antitumor and protumor activities of major structural and functional subsets of human γδ T cells, describing how these subsets are activated and polarized, and how these events relate to subsequent effects in cancer immunity. A mixture of both antitumor or protumor γδ T cells used in adoptive immunotherapy, coupled with the fact that γδ T cells can be polarized from antitumor cells to protumor cells appear to be the likely reasons for the mild efficacy seen with γδ T cells. Conclusion The future holds the promise of depleting the specific protumor γδ T cell subgroup before therapy, choosing multi-immunocyte adoptive therapy, modifying the cytokine balance in the cancer microenvironment, and using a combination of γδ T cells adoptive immunotherapy with immune checkpoint inhibitors.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Health & Fitness
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,626,432 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't see how the site brings in money.

Many websites are intended to earn money, but some serve to share ideas or build connections. Websites exist for all kinds of purposes. This might be one of them. Link.springer.com has a revenue plan, but it's either invisible or we haven't found it.

Keywords {🔍}

cells, pubmed, cancer, cell, article, google, scholar, cas, gammadelta, antitumor, central, human, immunol, immunotherapy, immune, tumor, protumor, function, adoptive, role, tme, patients, promote, cytokine, carcinoma, peripheral, cytokines, cytotoxicity, lymphocytes, activity, regulatory, blood, development, tcr, polarization, treg, induce, progression, angiogenesis, clinical, expansion, res, research, shown, subsets, effects, therapy, cytotoxic, growth, receptor,

Topics {✒️}

anti-cd3/anti-cd28 stimulated pbmcs chao niu & jiuwei cui myeloid-derived suppressor cells gammadelta t-cell-derived cytokines article download pdf th1/th2/th17 cytokine secretion convert tumor-elicited inflammation antibody-dependent anti-cytomegalovirus activity tumor-infiltrating il-17-producing gammadelta convert cancer-elicited inflammation gammadelta t-cell repertoire hbv-related hepatocellular carcinoma car t-cell therapy il-17a-producing cd30 cell-mediated cytotoxicity activity multi-immunocyte adoptive therapy hormone-refractory prostate cancer human gammadeltat-cell subsets counter-acting immune surveillance t-cell receptor delta small-cell lung cancer stat3/giv signaling pathway multi-immunocyte adoptive immunotherapy tumor-induced neutrophils acquire tcr-stat6 dependent manner tumor-derived γδ regulatory stimulating g-csf production chronic lymphocytic leukemia cea peptide-pulsed gammadelta perforin-granzyme secretion capacity professional antigen-presentation function tumor antigen-presenting capacity inflammation-induced cancer progression recognize stress-induced molecules fas/fas ligand pathway pro-angiogenic molecular mediators tumor-infiltrating gamma delta direct/indirect antitumor cytotoxicity cytokine-induced killer cells dendritic cell-based immunotherapy tumor-specific adaptive response perforin-granzyme lytic activity �γδ-resistant” hematopoietic malignancy cell-based adaptive immunotherapy strongly secrete tgf-β cell-based cancer immunotherapy vdelta2-negative gammadeltat cells interleukin-2 receptor beta-chain cancer antigen-specific cd8+ il-36γ acts synergistically

Questions {❓}

Can γδ T cells inhibit cancer growth on the one hand, and promote cancer development on the other?
Cytotoxic and regulatory properties of circulating Vdelta1+ gammadelta T cells: a new player on the cell therapy field?
Gamma-delta (γδ) T cells: friend or foe in cancer development?
Gamma-delta (γδ) T cells: friend or foe in cancer development?
Gammadelta T-APCs: a novel tool for immunotherapy?
Human gamma delta T regulatory cells in cancer: fact or fiction?
What lessons can be learned from γδ T cell-based cancer immunotherapy trials?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Gamma-delta (γδ) T cells: friend or foe in cancer development?
         description:γδ T cells are a distinct subgroup of T cells containing T cell receptors (TCRs) γ and TCR δ chains with diverse structural and functional heterogeneity. As a bridge between the innate and adaptive immune systems, γδ T cells participate in various immune responses during cancer progression. Because of their direct/indirect antitumor cytotoxicity and strong cytokine production ability, the use of γδ T cells in cancer immunotherapy has received a lot of attention over the past decade. Despite the promising potential of γδ T cells, the efficacy of γδ T cell immunotherapy is limited, with an average response ratio of only 21%. In addition, research over the past 2 years has shown that γδ T cells could also promote cancer progression by inhibiting antitumor responses, and enhancing cancer angiogenesis. As a result, γδ T cells have a dual effect and can therefore be considered as being both “friends” and “foes” of cancer. In order to solve the sub-optimal efficiency problem of γδ T cell immunotherapy, we review recent observations regarding the antitumor and protumor activities of major structural and functional subsets of human γδ T cells, describing how these subsets are activated and polarized, and how these events relate to subsequent effects in cancer immunity. A mixture of both antitumor or protumor γδ T cells used in adoptive immunotherapy, coupled with the fact that γδ T cells can be polarized from antitumor cells to protumor cells appear to be the likely reasons for the mild efficacy seen with γδ T cells. The future holds the promise of depleting the specific protumor γδ T cell subgroup before therapy, choosing multi-immunocyte adoptive therapy, modifying the cytokine balance in the cancer microenvironment, and using a combination of γδ T cells adoptive immunotherapy with immune checkpoint inhibitors.
         datePublished:2018-01-10T00:00:00Z
         dateModified:2018-05-08T00:00:00Z
         pageStart:1
         pageEnd:13
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s12967-017-1378-2
         keywords:
            γδ T cells
            Adoptive immunotherapy
            Protumor
            Antitumor
            Tumor microenvironment
            Cytokine
            Polarization
            Biomedicine
            general
            Medicine/Public Health
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-017-1378-2/MediaObjects/12967_2017_1378_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-017-1378-2/MediaObjects/12967_2017_1378_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-017-1378-2/MediaObjects/12967_2017_1378_Fig3_HTML.gif
         isPartOf:
            name:Journal of Translational Medicine
            issn:
               1479-5876
            volumeNumber:16
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Yijing Zhao
               affiliation:
                     name:The First Hospital of Jilin University
                     address:
                        name:Cancer Center, The First Hospital of Jilin University, Changchun, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Chao Niu
               affiliation:
                     name:The First Hospital of Jilin University
                     address:
                        name:Cancer Center, The First Hospital of Jilin University, Changchun, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jiuwei Cui
               affiliation:
                     name:The First Hospital of Jilin University
                     address:
                        name:Cancer Center, The First Hospital of Jilin University, Changchun, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Gamma-delta (γδ) T cells: friend or foe in cancer development?
      description:γδ T cells are a distinct subgroup of T cells containing T cell receptors (TCRs) γ and TCR δ chains with diverse structural and functional heterogeneity. As a bridge between the innate and adaptive immune systems, γδ T cells participate in various immune responses during cancer progression. Because of their direct/indirect antitumor cytotoxicity and strong cytokine production ability, the use of γδ T cells in cancer immunotherapy has received a lot of attention over the past decade. Despite the promising potential of γδ T cells, the efficacy of γδ T cell immunotherapy is limited, with an average response ratio of only 21%. In addition, research over the past 2 years has shown that γδ T cells could also promote cancer progression by inhibiting antitumor responses, and enhancing cancer angiogenesis. As a result, γδ T cells have a dual effect and can therefore be considered as being both “friends” and “foes” of cancer. In order to solve the sub-optimal efficiency problem of γδ T cell immunotherapy, we review recent observations regarding the antitumor and protumor activities of major structural and functional subsets of human γδ T cells, describing how these subsets are activated and polarized, and how these events relate to subsequent effects in cancer immunity. A mixture of both antitumor or protumor γδ T cells used in adoptive immunotherapy, coupled with the fact that γδ T cells can be polarized from antitumor cells to protumor cells appear to be the likely reasons for the mild efficacy seen with γδ T cells. The future holds the promise of depleting the specific protumor γδ T cell subgroup before therapy, choosing multi-immunocyte adoptive therapy, modifying the cytokine balance in the cancer microenvironment, and using a combination of γδ T cells adoptive immunotherapy with immune checkpoint inhibitors.
      datePublished:2018-01-10T00:00:00Z
      dateModified:2018-05-08T00:00:00Z
      pageStart:1
      pageEnd:13
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s12967-017-1378-2
      keywords:
         γδ T cells
         Adoptive immunotherapy
         Protumor
         Antitumor
         Tumor microenvironment
         Cytokine
         Polarization
         Biomedicine
         general
         Medicine/Public Health
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-017-1378-2/MediaObjects/12967_2017_1378_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-017-1378-2/MediaObjects/12967_2017_1378_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-017-1378-2/MediaObjects/12967_2017_1378_Fig3_HTML.gif
      isPartOf:
         name:Journal of Translational Medicine
         issn:
            1479-5876
         volumeNumber:16
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Yijing Zhao
            affiliation:
                  name:The First Hospital of Jilin University
                  address:
                     name:Cancer Center, The First Hospital of Jilin University, Changchun, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Chao Niu
            affiliation:
                  name:The First Hospital of Jilin University
                  address:
                     name:Cancer Center, The First Hospital of Jilin University, Changchun, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jiuwei Cui
            affiliation:
                  name:The First Hospital of Jilin University
                  address:
                     name:Cancer Center, The First Hospital of Jilin University, Changchun, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Journal of Translational Medicine
      issn:
         1479-5876
      volumeNumber:16
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:The First Hospital of Jilin University
      address:
         name:Cancer Center, The First Hospital of Jilin University, Changchun, People’s Republic of China
         type:PostalAddress
      name:The First Hospital of Jilin University
      address:
         name:Cancer Center, The First Hospital of Jilin University, Changchun, People’s Republic of China
         type:PostalAddress
      name:The First Hospital of Jilin University
      address:
         name:Cancer Center, The First Hospital of Jilin University, Changchun, People’s Republic of China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Yijing Zhao
      affiliation:
            name:The First Hospital of Jilin University
            address:
               name:Cancer Center, The First Hospital of Jilin University, Changchun, People’s Republic of China
               type:PostalAddress
            type:Organization
      name:Chao Niu
      affiliation:
            name:The First Hospital of Jilin University
            address:
               name:Cancer Center, The First Hospital of Jilin University, Changchun, People’s Republic of China
               type:PostalAddress
            type:Organization
      name:Jiuwei Cui
      affiliation:
            name:The First Hospital of Jilin University
            address:
               name:Cancer Center, The First Hospital of Jilin University, Changchun, People’s Republic of China
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Cancer Center, The First Hospital of Jilin University, Changchun, People’s Republic of China
      name:Cancer Center, The First Hospital of Jilin University, Changchun, People’s Republic of China
      name:Cancer Center, The First Hospital of Jilin University, Changchun, People’s Republic of China

External Links {🔗}(407)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.57s.

LINK . SPRINGER . COM {}